Glucotrack (GCTK) Common Equity (2016 - 2020)
Historic Common Equity for Glucotrack (GCTK) over the last 7 years, with Q3 2020 value amounting to $9.9 million.
- Glucotrack's Common Equity rose 125280.79% to $9.9 million in Q3 2020 from the same period last year, while for Sep 2020 it was $9.9 million, marking a year-over-year increase of 125280.79%. This contributed to the annual value of -$1.4 million for FY2019, which is 5085.79% up from last year.
- Glucotrack's Common Equity amounted to $9.9 million in Q3 2020, which was up 125280.79% from $10.4 million recorded in Q2 2020.
- Glucotrack's 5-year Common Equity high stood at $10.9 million for Q1 2020, and its period low was -$17.0 million during Q2 2018.
- For the 5-year period, Glucotrack's Common Equity averaged around -$6.1 million, with its median value being -$9.9 million (2016).
- As far as peak fluctuations go, Glucotrack's Common Equity tumbled by 7581.74% in 2016, and later surged by 6779364.86% in 2020.
- Quarter analysis of 5 years shows Glucotrack's Common Equity stood at -$10.9 million in 2016, then crashed by 51.38% to -$16.6 million in 2017, then skyrocketed by 82.66% to -$2.9 million in 2018, then surged by 50.86% to -$1.4 million in 2019, then soared by 804.43% to $9.9 million in 2020.
- Its Common Equity was $9.9 million in Q3 2020, compared to $10.4 million in Q2 2020 and $10.9 million in Q1 2020.